Match!
Michael J. Parnham
Fraunhofer Society
189Publications
32H-index
3,548Citations
Publications 170
Newest
#1Michael J. Parnham (Goethe University Frankfurt)H-Index: 32
#2Adriano G. Rossi (Edin.: University of Edinburgh)H-Index: 54
In the second half of the nineteenth century, Eli Metchnikoff discovered that bacteria can be ingested (phagocytosed) by LEUKOCYTES present in the blood of a variety of animals. At about the same time, Paul Ehrlich found that certain agents dissolved in blood had bactericidal potential. The scientific discussion on the importance of cellular versus humoral factors in our defense against bacteria that followed came to an end when it was recognized that both components enforce each other’s effect ...
Source
#1Michael J. Parnham (Fraunhofer Society)H-Index: 32
#2Gerd Geisslinger (Fraunhofer Society)H-Index: 66
Paul Ehrlich's concept of the magic bullet, by which a single drug induces pharmacological effects by interacting with a single receptor has been a strong driving force in pharmacology for a century. It is continually thwarted, though, by the fact that the treated organism is highly dynamic and the target molecule(s) is (are) never static. In this article, we address some of the factors that modify and cause the mobility and plasticity of drug targets and their interactions with ligands and disc...
Source
#1Ellen Niederberger (Goethe University Frankfurt)H-Index: 24
#2Michael J. Parnham (Fraunhofer Society)H-Index: 32
Last.Gerd Geisslinger (Fraunhofer Society)H-Index: 66
view all 4 authors...
Patient therapy is based mainly on a combination of diagnosis, suitable monitoring or support devices and drug treatment and is usually employed for a pre‐existing disease condition. Therapy remains predominantly symptom‐based, although it is increasingly clear that individual treatment is possible and beneficial. However, reasonable precision medicine can only be realized with the coordinated use of diagnostics, devices and drugs in combination with extensive databases (4Ds), an approach that h...
1 CitationsSource
#1Victor Hernandez-Olmos (Fraunhofer Society)H-Index: 1
#2Tilo Knape (Fraunhofer Society)H-Index: 3
Last.Ewgenij Proschak (Fraunhofer Society)H-Index: 25
view all 13 authors...
Abstract Peroxisome proliferator-activated receptor gamma (PPARγ) modulators have found wide application for the treatment of cancers, metabolic disorders and inflammatory diseases. Contrary to PPARγ agonists, PPARγ antagonists have been much less studied and although they have shown immunomodulatory effects, there is still no therapeutically useful PPARγ antagonist on the market. In contrast to non-competitive, irreversible inhibition caused by 2-chloro-5-nitrobenzanilide (GW9662), the recently...
Source
#1Marco Sisignano (Goethe University Frankfurt)H-Index: 13
#2Jörn Lötsch (Goethe University Frankfurt)H-Index: 56
Last.Gerd Geisslinger (Fraunhofer Society)H-Index: 66
view all 4 authors...
Abstract Persistent, in particular neuropathic pain affects millions of people worldwide. However, the response rate of patients to existing analgesic drugs is less than 50%. There are several possibilities to increase this response rate, such as optimization of the pharmacokinetic and pharmacodynamic properties of analgesics. Another promising approach is to use prognostic biomarkers in patients to determine the optimal pharmacological therapy for each individual. Here, we discuss recent effort...
1 CitationsSource
#1Marco Sisignano (Goethe University Frankfurt)H-Index: 13
#2Michael J. Parnham (Fraunhofer Society)H-Index: 32
Last.Gerd Geisslinger (Fraunhofer Society)H-Index: 66
view all 3 authors...
Persistent and neuropathic pain affects > 15% of the global population. Apart from being an individual burden to the patient, persistent pain causes considerable subsequent costs in global healthcare systems. Despite the efforts of pharmaceutical companies to develop novel analgesics, pharmacological options for the therapy of persistent and/or neuropathic pain are limited. We discuss here novel approaches to persistent pain therapy that are independent of classical target-based drug discovery, ...
Source
#1S. Mojtahed Poor (Fraunhofer Society)H-Index: 1
#2Thomas Ulshöfer (Fraunhofer Society)H-Index: 4
Last.Susanne Schiffmann (Fraunhofer Society)H-Index: 21
view all 10 authors...
1 CitationsSource
#1Yingying Han (Goethe University Frankfurt)H-Index: 2
#2Javier Mora (UCR: University of Costa Rica)H-Index: 10
Last.Andreas Weigert (Goethe University Frankfurt)H-Index: 30
view all 20 authors...
Summary Interleukin-38 (IL-38) is a cytokine of the IL-1 family with a role in chronic inflammation. However, its main cellular targets and receptors remain obscure. IL-38 is highly expressed in the skin and downregulated in psoriasis patients. We report an investigation in cellular targets of IL-38 during the progression of imiquimod-induced psoriasis. In this model, IL-38 knockout (IL-38 KO) mice show delayed disease resolution with exacerbated IL-17-mediated inflammation, which is reversed by...
5 CitationsSource
#1Lisa Nothnagel (Fraunhofer Society)H-Index: 2
#2Fabian Jung (Fraunhofer Society)H-Index: 2
Last.Matthias G. Wacker (Fraunhofer Society)H-Index: 13
view all 8 authors...
Abstract Since many drugs in the therapy scheme of multiple sclerosis (MS) are applied parenterally with significant side effects, oral treatment is the most accepted therapy option for chronic diseases like MS. The drug candidate TMP-001, which has disease-modifying properties, can be applied orally. Beside other symptoms, swallowing disorders have a major impact not only on the health status and quality of life of MS patients, but also impede reliable drug therapy. Consequently, the developmen...
1 CitationsSource
#2Andreas von KnethenH-Index: 16
Last.Tilo KnapeH-Index: 3
view all 16 authors...
Source
12345678910